Addex Therapeutics Ltd (ADXN) Income Statement
ADXN 2025 at a glance
Fiscal year ended December 31, 2025 · Swiss francsADXN revenue and net income
Where ADXN's revenue goes
2025Each bar shows an amount and its share of revenue. ADXN kept −22,448.4% of revenue as net income.
ADXN profit margins
ADXN growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −92.6% | −72.4% | −61.6% | −2.9% |
| Gross profit | −92.6% | −72.4% | −61.6% | −0.0% |
| Operating income | — | — | — | — |
| Net income | −195.4% | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ADXN income statement in Swiss francs
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | CHF 29,972 | CHF 404,102 | CHF 1.6M | CHF 1.4M | CHF 2.9M | CHF 3.6M | CHF 2.8M | CHF 6.0M | CHF 499,894 | CHF 17,329 |
| Cost of revenue | CHF 10,201 | CHF 854,305 | CHF 6.9M | CHF 14.6M | CHF 12.8M | CHF 10.4M | CHF 230,097 | CHF 144,169 | CHF 29,764 | CHF 17,329 |
| Gross profit | CHF 29,972 | CHF 404,102 | CHF 1.6M | CHF 1.4M | CHF 2.9M | CHF 3.6M | CHF 2.5M | CHF 5.9M | CHF 470,130 | −CHF 407,586 |
| Research & development | CHF 190,190 | CHF 435,189 | CHF 942,714 | CHF 7.9M | CHF 9.0M | CHF 10.4M | CHF 12.5M | CHF 2.4M | CHF 841,308 | CHF 819,330 |
| Sales, general & admin | CHF 1.9M | CHF 1.7M | CHF 2.0M | CHF 3.3M | CHF 7.7M | CHF 5.7M | CHF 4.3M | CHF 4.7M | CHF 2.2M | CHF 1.5M |
| Total operating expenses | CHF 2.8M | CHF 3.2M | CHF 3.9M | CHF 12.0M | CHF 18.4M | CHF 15.9M | CHF 17.1M | CHF 7.5M | CHF 3.2M | CHF 3.1M |
| Operating income | −CHF 2.8M | −CHF 2.8M | −CHF 2.2M | −CHF 10.5M | −CHF 15.5M | −CHF 12.2M | −CHF 14.6M | −CHF 1.4M | −CHF 3.2M | −CHF 3.1M |
| Interest income | CHF 0 | CHF 9,165 | CHF 63,964 | CHF 29,251 | CHF 5,322 | CHF 35,305 | CHF 176,450 | CHF 220,180 | CHF 45,350 | CHF 19,790 |
| Interest expense | CHF 2,421 | CHF 3,547 | CHF 21,607 | CHF 48,897 | CHF 63,012 | CHF 69,502 | CHF 128,518 | CHF 220,173 | CHF 45,350 | CHF 6,924 |
| Income before taxes | −CHF 6.8M | −CHF 4.9M | −CHF 2.5M | −CHF 10.8M | −CHF 15.4M | −CHF 12.9M | −CHF 14.8M | −CHF 1.6M | −CHF 3.3M | −CHF 3.1M |
| Income taxes | — | — | CHF 21,607 | CHF 123,910 | CHF 116,377 | CHF 207,762 | CHF 429,009 | CHF 1 | — | CHF 6,924 |
| Net income | −CHF 6.7M | CHF 7.1M | −CHF 10.6M | −CHF 20.8M | −CHF 15.4M | −CHF 12.9M | −CHF 14.8M | −CHF 1.6M | −CHF 3.3M | −CHF 3.1M |
| EBITDA | −CHF 6.8M | −CHF 4.6M | −CHF 2.2M | −CHF 10.5M | −CHF 14.9M | −CHF 12.4M | −CHF 14.3M | −CHF 1.5M | −CHF 3.2M | −CHF 3.1M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 91.7% | 97.6% | 94.0% | −2,352.0% |
| Operating margin | −9,390.8% | −681.8% | −139.1% | −741.0% | −531.7% | −338.9% | −528.6% | −23.6% | −647.1% | −18,059.9% |
| Net margin | −22,448.4% | 1,746.0% | −654.5% | −1,462.6% | −526.4% | −355.9% | −535.0% | −27.2% | −656.2% | −18,174.1% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | CHF 9,908 | CHF 7,691 | CHF 19,806 | CHF 29,724 | CHF 36,375 | CHF 1,508 | CHF 1,508 | CHF 53,837 | CHF 115,277 | CHF 233,480 | CHF 153,451 | CHF 327,733 |
| Cost of revenue | CHF 25,127 | CHF 36,129 | CHF 2,650 | CHF 0 | CHF 234,454 | CHF 156,066 | — | CHF 0 | CHF 338,317 | −CHF 90 | CHF 1.5M | CHF 1.8M |
| Gross profit | −CHF 15,217 | −CHF 28,438 | CHF 17,156 | CHF 29,724 | −CHF 198,079 | CHF 1,508 | — | CHF 53,837 | CHF 115,277 | CHF 233,480 | −CHF 1.4M | CHF 327,733 |
| Research & development | CHF 37,850 | CHF 9,394 | CHF 66,075 | CHF 85,256 | CHF 68,492 | CHF 32,583 | CHF 6,229 | CHF 77,847 | CHF 184,461 | CHF 179,110 | CHF 454,305 | CHF 421,153 |
| Sales, general & admin | CHF 617,314 | CHF 389,315 | CHF 567,981 | CHF 459,919 | CHF 411,956 | CHF 448,074 | CHF 260,566 | CHF 337,248 | CHF 509,166 | CHF 774,939 | CHF 1.7M | CHF 473,988 |
| Total operating expenses | CHF 627,604 | CHF 451,389 | CHF 992,182 | CHF 725,899 | CHF 534,819 | CHF 606,262 | CHF 447,134 | CHF 676,036 | CHF 1.0M | CHF 1.0M | CHF 2.8M | CHF 1.1M |
| Operating income | −CHF 642,471 | −CHF 479,827 | −CHF 975,025 | −CHF 696,175 | −CHF 732,898 | −CHF 606,262 | −CHF 445,626 | −CHF 622,199 | −CHF 899,316 | −CHF 788,092 | −CHF 2.7M | −CHF 749,238 |
| Interest income | — | — | CHF 0 | CHF 0 | CHF 3 | — | CHF 15 | CHF 102 | CHF 1,507 | CHF 7,571 | CHF 13,131 | CHF 13,658 |
| Interest expense | CHF 1,170 | CHF 3,066 | CHF 719 | CHF 472 | CHF 829 | CHF 548 | CHF 1,486 | CHF 586 | CHF 864 | CHF 611 | CHF 8,356 | CHF 3,503 |
| Income before taxes | −CHF 1.7M | −CHF 1.7M | −CHF 2.3M | −CHF 1.6M | −CHF 2.0M | −CHF 1.5M | −CHF 1.2M | −CHF 1.5M | −CHF 1.5M | −CHF 735,178 | −CHF 2.9M | −CHF 710,736 |
| Income taxes | — | — | — | — | — | — | — | — | −CHF 14.9M | CHF 3.1M | CHF 8,356 | CHF 3,503 |
| Net income | −CHF 1.7M | −CHF 1.7M | −CHF 2.3M | −CHF 1.6M | −CHF 1.8M | −CHF 1.5M | −CHF 1.2M | −CHF 1.5M | CHF 12.9M | −CHF 3.1M | −CHF 2.9M | −CHF 2.6M |
| EBITDA | −CHF 617,695 | −CHF 1.7M | −CHF 972,375 | −CHF 1.6M | −CHF 2.0M | −CHF 1.5M | — | −CHF 1.5M | −CHF 1.3M | −CHF 664,207 | −CHF 2.8M | −CHF 634,817 |
| Gross margin | −153.6% | −369.8% | 86.6% | 100.0% | −544.5% | 100.0% | — | 100.0% | 100.0% | 100.0% | −907.7% | 100.0% |
| Operating margin | −6,484.4% | −6,238.8% | −4,922.9% | −2,342.1% | −2,014.8% | −40,203.1% | −29,550.8% | −1,155.7% | −780.1% | −337.5% | −1,748.1% | −228.6% |
| Net margin | −17,543.0% | −22,256.4% | −11,604.9% | −5,306.3% | −5,061.6% | −97,670.0% | −79,956.0% | −2,841.9% | 11,171.9% | −1,322.2% | −1,861.7% | −798.5% |
Quarterly columns are labeled by the month the quarter ended. Figures in Swiss francs as reported in ADXN's financial statements (latest annual report filed May 15, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ADXN financial results
In fiscal year 2025 (ended December 31, 2025), Addex Therapeutics reported revenue of CHF 0.0 million, down 92.6% from the year before. It had a net loss of CHF 6.7 million, a net profit margin of −22,448.4%. Over five years revenue grew at an average rate of −61.6% a year. Figures are in Swiss francs, the currency of its financial statements.
See the ADXN stock overview for the latest quote and news, or the ADXN chart for price history and technical indicators.
ADXN income statement FAQ
What is Addex Therapeutics's annual revenue?
Addex Therapeutics reported total revenue of CHF 0.0 million for fiscal year 2025, which ended on December 31, 2025. That was down 92.6% from CHF 0.4 million the previous year.
Is Addex Therapeutics profitable?
No. Addex Therapeutics reported a net loss of CHF 6.7 million in fiscal 2025, a net profit margin of −22,448.4%; its operating margin was −9,390.8%.
What is Addex Therapeutics's gross margin?
Addex Therapeutics's gross margin was 100.0% in fiscal 2025: for every $100 of revenue, Addex Therapeutics kept $100 after the direct cost of its products and services.
How much does Addex Therapeutics spend on research and development?
Addex Therapeutics spent CHF 0.2 million on research and development in fiscal 2025, 634.6% of revenue.
How fast is Addex Therapeutics growing?
Revenue grew −61.6% a year on average over the last five fiscal years, from CHF 3.6 million to CHF 0.0 million.
When will Addex Therapeutics report its next earnings?
Addex Therapeutics is expected to report results for the quarter ending September 30, 2026 on December 3, 2026.
When does Addex Therapeutics's fiscal year end?
Addex Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on May 15, 2026.